A445 indirect costs (versus 0) and the probability that patients with positive costs spent more than a4000 (versus less than a4000). RESULTS: Out of the 3494 questionnaires mailed 1189 (34.0%) were returned and fully completed. The mean age of respondents was 53.1 years (SD 8.6); 85.4% were women and the mean RA duration was 14.7 years (SD 9.7). At the time of the survey, 49.9% of respondents were employed, 32.7% declared being on RA work disability perceiving pension invalidity. A total of 45.3% of employed patients had at least one sick leave over the past 6 months, with on average a cumulative duration of 11.6 days over. The average annual estimated indirect cost was a3210 (74.4% RA-related work disability and 25.6% due to RA sick leaves). The three main risk factors associated with higher costs were: failure of at least one biotherapy (Odds Ratio-OR 4.8), RA poor functional status (severe HAQ versus mild HAQ, OR 3.8) and on-going treatment (disease-modifying antirheumatic drugs versus etanercept, OR 3.5). A high level of education is protective (OR 0.6). UK OBJECTIVES: Rituximab and infliximab are biologic disease modifying antirheumatic drugs (DMARDS) used to treat rheumatoid arthritis (RA). Rituximab is re-dosed when signs and symptoms return, but infliximab has fixed dosing intervals. This 3-centre observational study was to determine the secondary care resource and patient time implications of this difference. METHODS: Medical records of 44 patients with RA, treated with infliximab (n 26) or at least 2 courses of rituximab (n 18) were reviewed retrospectively to determine mean time between end of 1st rituximab course and start of the 2nd, and numbers of visits and investigations for both drugs. Staff and patient time required for drug administration was measured prospectively by direct observation of 25 patients receiving infliximab (n 13) or rituximab (n 12). RESULTS: Mean time between 1st and 2nd courses of rituximab was 43 weeks (range 15-84). During this time a mean of 6.9 (range 4-8) infliximab infusions was administered. Rituximab-treated patients required 2 visits for drug administration during this time, vs. infliximab 6.9 visits. Each visit required a mean of 87.2 minutes of staff time for rituximab patients vs. 46.0 minutes for infliximab. Total staff time per patient over 43 weeks was 2.9 hours for rituximab vs. 5.3 hours for infliximab. Mean total patient time in the unit per 43 weeks was 14.1 hours for rituximab vs. 25.3 hours for infliximab. CONCLUSIONS: Although rituximab requires almost twice as much staff time per visit for its administration as infliximab, it is administered less often so staff time required over a whole course is less for rituximab than infliximab. An even greater difference was seen for patient time spent on the unit for drug administration. This study demonstrates benefits from rituximab in terms of patient convenience and staff efficiency, which can inform NHS planning of service delivery and quality standards for patients with RA.
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ANALYSIS OF HOSPITAL EVENTS MEANING IATROGENICITY, ANHEMIA
Vainchtock A 1 , Kosa M 2 , Diazaraque R 3 , Lamarsalle L 1 , Duru G 4 1 HEVA Health Evaluation, Lyon, France, 2 PFIZER FRANCE, Paris, France, 3 PFIZER, Walton Oaks, UK, 4 Université Caude Bernard, Lyon, France OBJECTIVES: Anaemia is prevalent among old individuals. Iron deficiency due to chronic gastrointestinal loss is a frequent cause. Non-steroidal anti-inflammatory drugs (NSAIDs) are a major cause of bleeding among osteoarthritis (OA) patients. Analysis of Hospital Events Meaning IAtrogenicity (ANHEMIA) study aims at assessing the demographic characteristics of anaemia in french OA patients and its impact on hospital length of stay (LOS). METHODS: Programme de Médicalisation des Systèmes d'Information (PMSI) database covers french hospital activity and is used by Health Authorities as resources use indicators for allocating and forecasting medical budget. Its Use to assess the epidemiological and economic burden of illness is recommended. Cross-linkage through the ICD-10 diagnosis codes allowed the identification of hospital stays with a main diagnosis of osteoarthritis (OA ) and Among these, 2 subpopulations according to the existence or absence of iron-deficiency anaemia (AN or AN-). ICD-10 diagnosis cancers were excluded. Four groups were established for analysis: OA AN-, OA AN in either private or public hospitals (PrH, PuH). RESULTS: All the groups analysis showed a higher percentage of women (p 0.001): 2 out of every 3 patients. In PuH, mean age of OA AN patients was 73.5 years vs. 65.3 for OA AN-patients, in PrH: 69.0 years (OA AN ) vs. 58.3 (OA AN-). Overall, OA AN patients were significantly older than 65 compared to OA ANpatients: 88.1% vs. 68.7% (p 0.001) both in PrH or PuH. Compared to OA ANpatients, OA AN patients had a longer LOS: 2.58 days in PuH, 2.49 days in PrH for matched DRG. The increase in LOS was accountable for substantial extra costs: a791,504 for PuH and a760,080 for PrH for the year 2006. CONCLUSIONS: Anaemia, is an important driver for extra-costs in hospitalized OA population. Since this population is likely to grow in the forthcoming years, every effort to reduce its incidence of anaemia should be considered. The two main procedures were posterior lumbar arthrodesis (procedure code LFDA004/0; n 68) and removal of herniated disc (procedure code LFFA002/0; n 111). For posterior lumbar arthrodesis surgery, the average LOS in Foch Hospital was 5.9 days compared to 8.9 days in the national data base (34% decrease). For herniated disc surgery, the average LOS in Foch hospital was 3.4 days compared to 5.3 days in the national data base (36% decrease). In 2007, Foch hospital avoided 215 days of hospitalization with the MAST, representing between a133,000 and a141,000 (a320-a340 per day). CONCLUSIONS: By lowering morbidity and reducing recovery time, MAST TM reduces costs of hospital stays. The reduction of hospital days may off-set any additional device costs. Further prospective research should be considered to validate our findings; however this is one of the first studies investigating systematically this subject. prescribed to assumed number of therapy units). MPR 80% assumed compliance. MPR was calculated for patients on therapy up to 2 years. Fractures were identified by ICD-10 codes; only fractures 3 months after initiating oBP were included. The influence of compliance on time to fracture was determined by Kaplan-Meier and Cox regression analyses. The model was adjusted for gender, age, prevalence of fractures 1 year before index prescription, calcium/vitamin D co-prescription, continuation of the initial regimen after 6 months and after 1 year. RESULTS: A total of 4738 patients' data were analyzed: 1365 (28.8%) with previous fractures. The total number of patients receiving oBP treatment was 177 (3.7%) daily, 4367 (92.2%) weekly and 194 (4.1%) monthly. After 2 years, 14.5% (daily), 12.2% (weekly), and 9.7% (monthly) of patients experienced a fracture. The time to fracture was significantly longer for compliant versus non-compliant patients (log rank test; p 0.013). Compliance was associated with a 26% (95% CI 10-39%) decrease in the fracture rate versus non-compliance. Higher age ( 60 years) (44% increase; 95%CI 3-100%) and previous fractures (29% increase; 95%CI 5-57%) were associated with a significantly higher risk of fractures. CONCLUSIONS: Patients receiving oBP therapy who are compliant have a decreased risk of fractures versus non-compliant patients. Older patients and those with fracture history are particularly at risk of fracture. These findings highlight the need to improve compliance to reduce the risk of osteoporosisassociated fractures.
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IMPACT OF MINIMAL ACCESS SPINAL TECHNOLOGIES (MAST TM ) ON HOSPITALIZATION COST: A FRENCH EXPERIENCE
MUSCULAR-SKELETAL DISORDERS -Patient-Reported Outcome Studies
PMS66 GRAND: THE GERMAN RETROSPECTIVE COHORT ANALYSIS ON NON-ADHERENCE AND ASSOCIATED RISK OF FRACTURES IN OSTEOPOROSIS PATIENTS TREATED WITH ORAL BISPHOSPHONATES
PMS67 THE EFFECT OF MEDICATION CHOICE BETWEEN DULOXETINE AND PREGABALIN ON MEDICATION COMPLIANCE AND DIRECT CARE COSTS AMONG PATIENTS WITH FIBROMYALGIA
Sun P 1 , Watson PR 2 , Mitchell BD 2 , Zhao Y 2 1 Kailo Research Group, Indianapolis, IN, USA, 2 Eli Lilly and Company, Indianapolis, IN, USA OBJECTIVES: To examine the effect of medication choice between duloxetine and pregabalin on medication compliance outcomes as well as direct health care costs among patients with fibromyalgia. METHODS: A retrospective cohort study design was used with a large US national commercial health care claims database over [2005] [2006] [2007] . Fibromyalgia patients aged 18-64 who initiated (no pill coverage in the previous 90 days) duloxetine or pregabalin in 2006 were selected, with the first initiation date as the index date. All patients included had continuous enrollment in the 12
